# Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours

> **NCT00809133** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 83 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** BIBW 2992
- **DRUG:** Paclitaxel
- **DRUG:** BIBW2992
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Bevacizumab
- **DRUG:** BIBW 2992
- **DRUG:** BIBW 2992

## Key facts

- **NCT ID:** NCT00809133
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2016-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00809133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00809133, "Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00809133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*